38
Views
0
CrossRef citations to date
0
Altmetric
PERSPECTIVES

The Pendulum: The Need to Develop a Safe, Effective, and Equitable Management Strategy for Opioids in Cancer Patients

&
Pages 1079-1082 | Received 16 Dec 2023, Accepted 11 Apr 2024, Published online: 24 Apr 2024

References

  • Ahmad FB, Cisewski JA, Rossen LM, Sutton P. Provisional drug overdose death counts. National Center for Health Statistics; 2023. Available from: https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm. Accessed April 12, 2024.
  • Volkow N, McClellan T, Longo DL. Opioid abuse in chronic pain--misconceptions and mitigation strategies. NEJM. 2016;374(13):1253–1263. doi:10.1056/NEJMra1507771
  • 18VAC85-21. Regulations Governing Prescribing of Opioids and Buprenorphine. Virginia Administrative Code. Available from: https://law.lis.virginia.gov/admincodefull/title18/agency85/chapter21/. Accessed April 12, 2024.
  • Paice JA, Bohlke K, Barton D, et al. Use of opioids for adults with pain from cancer or cancer treatment: ASCO guideline. J Clin Oncol off J Am Soc Clin Oncol. 2023;41(4):914–930. doi:10.1200/JCO.22.02198
  • Enzinger AC, Ghosh K, Keating NL, et al. Racial and ethnic disparities in opioid access and urine drug screening among older patients with poor-prognosis cancer near the end of life. J Clin Oncol off J Am Soc Clin Oncol. 2023;41(14):2511–2522. doi:10.1200/JCO.22.01413
  • Arthur J, Bruera E. Managing cancer pain in patients with opioid use disorder or nonmedical opioid use. JAMA Oncol. 2022;8(8):1104–1105. doi:10.1001/jamaoncol.2022.2150
  • Preux C, Bertin M, Tarot A, et al. Prevalence of opioid use disorder among patients with cancer-related pain: a systematic review. J Clin Med. 2022;11(6):1594. doi:10.3390/jcm11061594
  • Fitzgerald Jones K, Khodyakov D, Arnold R, et al. Consensus-based guidance on opioid management in individuals with advanced cancer-related pain and opioid misuse or use disorder. JAMA Oncol. 2022;8(8):1107–1114. doi:10.1001/jamaoncol.2022.2191
  • Center for Drug Evaluation and Research. FDA identifies harm reported from sudden discontinuation of opioid pain medicines and requires label changes to guide prescribers on gradual, individualized tapering (FDA Drug Safety Communication); 2019. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-identifies-harm-reported-sudden-discontinuation-opioid-pain-medicines-and-requires-label-changes. Accessed April 12, 2024.
  • Centers for Disease Control and Prevention. Pocket Guide: Tapering Opioids for Chronic Pain. Centers for Disease Control and Prevention. U.S: Department of Health and Human Services; 2017.
  • Davis MP, Digwood G, Mehta Z, McPherson ML. Tapering opioids: a comprehensive qualitative review. Ann Palliat Med. 2020;9(2):586–610. doi:10.21037/apm.2019.12.10
  • Fenton JJ, Magnan E, Tseregounis IE, Xing G, Agnoli AL, Tancredi DJ. Long-term risk of overdose or mental health crisis after opioid dose tapering. JAMA Network Open. 2022;5(6):e2216726–e2216726. doi:10.1001/jamanetworkopen.2022.16726
  • Larochelle MR, Lodi S, Yan S, Clothier BA, Goldsmith ES, Bohnert ASB. Comparative effectiveness of opioid tapering or abrupt discontinuation vs no dosage change for opioid overdose or suicide for patients receiving stable long-term opioid therapy. JAMA Network Open. 2022;5(8):e2226523–e2226523. doi:10.1001/jamanetworkopen.2022.26523
  • Arnold M, Rutherford MJ, Bardot A, et al. Progress in cancer survival, mortality, and incidence in seven high-income countries 1995–2014 (ICBP SURVMARK-2): a population-based study. Lancet Oncol. 2019;20(11):1493–1505. doi:10.1016/S1470-2045(19)30456-5
  • Bar J, Urban D, Amit U, et al. Long-term survival of patients with metastatic non-small-cell lung cancer over five decades. J Oncol. 2021;2021:7836264. doi:10.1155/2021/7836264
  • Shapiro CL. Cancer Survivorship. N Engl J Med. 2018;379(25):2438–2450. doi:10.1056/NEJMra1712502
  • Hoffman KM, Trawalter S, Axt JR, Oliver MN. Racial bias in pain assessment and treatment recommendations, and false beliefs about biological differences between blacks and whites. Proc Natl Acad Sci U S A. 2016;113(16):4296–4301. doi:10.1073/pnas.1516047113
  • Stein KD, Alcaraz KI, Kamson C, Fallon EA, Smith TG. Sociodemographic inequalities in barriers to cancer pain management: a report from the American Cancer Society’s Study of Cancer Survivors-II (SCS-II). Psycho-oncology. 2016;25(10):1212–1221. doi:10.1002/pon.4218
  • Choi HY, Graetz I, Shaban-Nejad A, et al. Social disparities of pain and pain intensity among women diagnosed with early stage breast cancer. Front Oncol. 2022;12:759272. doi:10.3389/fonc.2022.759272
  • Williams E. A Look at Changes in Opioid Prescribing Patterns in Medicaid from 2016 to 2019 | KFF. KFF; 2023. Available from: https://www.kff.org/medicaid/issue-brief/a-look-at-changes-in-opioid-prescribing-patterns-in-medicaid-from-2016-to-2019/. Accessed April 12, 2024.
  • National Academy for State Health Policy. State approaches for distribution of national opioid settlement funding. NASHP; 2023. Available from: https://nashp.org/state-approaches-for-distribution-of-national-opioid-settlement-funding/. Accessed April 12, 2024.
  • Collins SE, Clifasefi SL, Stanton J; The Leap Advisory Board null. Community-based participatory research (CBPR): towards equitable involvement of community in psychology research. Am Psychol. 2018;73(7):884–898. doi:10.1037/amp0000167
  • Springer MV, Skolarus LE. Community-based participatory research. Stroke. 2019;50(3):e48–50. doi:10.1161/STROKEAHA.118.024241
  • Tremblay MC, Martin DH, McComber AM, McGregor A, Macaulay AC. Understanding community-based participatory research through a social movement framework: a case study of the Kahnawake Schools Diabetes Prevention Project. BMC Public Health. 2018;18(1):487. doi:10.1186/s12889-018-5412-y
  • Patel MI, Kapphahn K, Wood E, et al. Effect of a community health worker–led intervention among low-income and minoritized patients with cancer: a randomized clinical trial. J Clin Oncol. 2023;2:00309.
  • Patel MI, Kapphahn K, Dewland M, et al. Effect of a community health worker intervention on acute care use, advance care planning, and patient-reported outcomes among adults with advanced stages of cancer: a randomized clinical trial. JAMA Oncol. 2022;8(8):1139–1148. doi:10.1001/jamaoncol.2022.1997
  • Goldstick JE, Guy GP, Losby JL, Baldwin G, Myers M, Bohnert ASB. Changes in initial opioid prescribing practices after the 2016 release of the CDC guideline for prescribing opioids for chronic pain. JAMA Network Open. 2021;4(7):e2116860–e2116860. doi:10.1001/jamanetworkopen.2021.16860
  • Meisenberg BR, Grover J, Campbell C, Korpon D. Assessment of opioid prescribing practices before and after implementation of a health system intervention to reduce opioid overprescribing. JAMA Network Open. 2018;1(5):e182908–e182908. doi:10.1001/jamanetworkopen.2018.2908
  • Pergolizzi JV, Raffa RB, Rosenblatt MH. Opioid withdrawal symptoms, a consequence of chronic opioid use and opioid use disorder: current understanding and approaches to management. J Clin Pharm Ther. 2020;45(5):892–903. doi:10.1111/jcpt.13114
  • de la Cruz M, Reddy A, Balankari V, et al. The impact of an educational program on patient practices for safe use, storage, and disposal of opioids at a comprehensive cancer center. oncologist. 2017;22(1):115–121. doi:10.1634/theoncologist.2016-0266